Hemophilia A - 41 Studies Found Completed : Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A : Hemophilia A : 2005-08-30 : Genetic: ReFacto AF Genetic: B-Domain dele Completed : Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment : Hemophilia A : 2008-02-04 : Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222) Active, not recruiting : A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A : Hemophilia A : 2012-03-28 : Biological: BAY94-9027 Intravenous infusion of BAY94-9027 Recruiting : Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." : Hemophilia A : 2015-10-20 : Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222) Completed : Study of Biostate® in Children With Hemophilia A : Hemophilia A : 2010-10-01 : Biological: Biostate 1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day Completed : Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery : Hemophilia A : 2006-07-25 : Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM) Completed : Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery : Hemophilia A : 2005-10-20 : Biological: ReFacto AF Recruiting : A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors : Hemophilia A : 2016-07-26 : Drug: Emicizumab Participants will receive emicizumab prophylaxis at the specified dose subcutaneously u Completed : Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A : Hemophilia A : 2012-03-22 : Drug: GreenGene Dose : 10 ~ 50IU/kg Administration method : intravenous infusion or bolus Enrolling by invitation : Platelet Function in Patients With Hemophilia A : Hemophilia A : 2014-03-19 <<< Previous | Next >>>